Oncologists have called for an overhaul of drug compendia cited in connection with off-label use reimbursement of cancer drugs. While there is insufficient evidence for some approved off-label uses of cancer drugs, having multiple sources is preferable to shoehorning into one reference guide.
Why It’s Not So Simple To Standardize The Guides Insurers Use To Pay For Off-Label Cancer Drugs
